Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10508547 | 0.87 | QDPR (0.50) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL23420907 | 0.83 | ACMSD (0.51) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL5213516 | 0.83 | ACMSD (0.56) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL7458427 | 0.81 | ACMSD (0.57) | QDPRTSHRHSD17B10ACMSDCA2 | |
| SCHEMBL10787094 | 0.81 | ACMSD (0.57) | QDPRTSHRHSD17B10ACMSDCA2 | |
| SCHEMBL7153005 | 0.80 | ESR2 (0.55) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL7153002 | 0.80 | ESR2 (0.55) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL31063246 | 0.79 | QDPR (0.43) | QDPRPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5214730 | 0.76 | QDPR (0.41) | QDPRTSHRHSD17B10ACMSDTTR | |
| SCHEMBL29566733 | 0.76 | QDPR (0.73) | QDPRPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194147-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194147-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2000078313-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-4078076-A | HYPOLIPEMIC ACTIVITY | ROUSSEL UCLAF (FR) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | QDPR 1784/4885TSHR 123/4885HSD17B10 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.